Evaluating AI-Gatekeeper Software in Coronary Artery Stenosis Screening: a Multicenter RCT

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

450 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-01

Study Completion Date

2025-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the efficacy, safety, and cost-effectiveness of AI-Gatekeeper software to assist clinicians in the diagnosis of coronary artery disease by predicting coronary artery stenosis (≥50%) from a multimodal AI technology that integrates clinical risk factors and baseline blood tests, including chest X-ray, electrocardiogram, and echocardiogram, in patients with suspected coronary artery disease (coronary stenosis).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AI-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary CTA

NCT06748261

Cardiovascular Diseases Hypertrophic Cardiomyopathy (HCM) Dilated Cardiomyopathy (DCM) +6 more

NOT_YET_RECRUITING

A CCTA Image Assisted Triage Software for the Assessment of Patients With Suspected Coronary Artery Disease

NCT06172985

Coronary Heart Disease

UNKNOWN

Risk Evaluation by COronary Imaging and Artificial intelliGence Based fuNctIonal analyZing tEchniques - IV

NCT06793787

Coronary Artery Disease Coronary Atheroscleroses Acute Coronary Syndromes (ACS) +1 more

RECRUITING

EEG/MECG/EMG Evaluating the Severity of Aortic Stenosis, Heart Failure and Ischemic Stroke Through an Artificial Intelligenceassisted System.

NCT05716659

CVD

NOT_YET_RECRUITING

CMR-AI and Outcomes in AS

NCT06128876

Aortic Stenosis

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Coronary artery disease (CAD) is a leading cause of global mortality, accounting for over 50% of heart disease-related deaths. Initial evaluations for CAD typically involve chest X-rays, electrocardiograms (ECG), risk factor assessments, and basic blood tests. However, these primary tests can't conclusively diagnose CAD. When CAD is suspected, coronary CTA (CCTA) or invasive coronary angiography (ICA) is performed, determining the need for procedures like stenting or revascularization.

Interestingly, over 50% of patients undergoing CCTA or ICA don't require treatment, as CAD is either absent or not severe enough. This leads to unnecessary procedures and significant healthcare costs. For instance, in the U.S., the cost of unnecessary ICAs reaches billions annually, with similar trends in South Korea.

AI-Gatekeeper software assists clinicians in diagnosing coronary artery disease by predicting coronary artery stenosis (≥50%) using multimodal AI technology. It integrates clinical risk factors and baseline blood tests, including chest X-ray, electrocardiogram, and echocardiogram, in patients with suspected coronary artery disease The purpose of this study is to determine the efficacy, safety, and cost-effectiveness of the AI-Gatekeeper software in a prospective, multicenter, randomized control trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease Diagnosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Assisted by the AI-Gatekeeper software group

After a baseline examination (chest X-ray, electrocardiogram, echocardiogram, clinical risk factors and blood test), the AI-Gatekeeper software will be used to guide clinical care.

Group Type EXPERIMENTAL

Assisted by the AI-Gatekeeper software group

Intervention Type DIAGNOSTIC_TEST

The group will be received a AI-Gatekeeper software report on the probability of having coronary artery stenosis (≥50%) based on the routine test.

Usual care group

The usual care group will be managed based on established guidelines.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Assisted by the AI-Gatekeeper software group

The group will be received a AI-Gatekeeper software report on the probability of having coronary artery stenosis (≥50%) based on the routine test.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A patient with symptoms such as chest pain suggestive of coronary artery disease, who underwent routine evaluations including blood tests, electrocardiogram, chest X-ray, and echocardiography
* Low to Intermediate risk of pretest probabilities of obstructive CAD
* Voluntarily agreed to participate in this clinical trial and signed the written consent form

Exclusion Criteria

* Acute chest pain (in patients who have not been ruled out for ACS)
* Previously diagnosed and treated coronary artery disease (myocardial infarction, PCI, CABG)
* Patients with a life expectancy of less than 2 years due to conditions other than heart disease
* Those who have not consented to the protocol
* Participated in a drug or medical device clinical trial within the last 3 months
* Pregnant or lactating women
* Allergic to iodine preparations
* Serum creatine level greater than 1.5 mg/dL or eGFR less than 30 mL/min
* Baseline irregular and uncontrolled heart rhythm
* Heart rate greater than 100 beats/minute
* Systolic blood pressure of 90 mm Hg or less
* Contraindications to beta blockers or nitroglycerin
* Patients with complex congenital heart disease
* Body mass index greater than or equal to 35

Minimum Eligible Age

19 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No